简介：我们的目标是系统地、结构性地分析和比较波兰和其他国家的报销制度。方法：这些系统是根据波兰卫生技术评估和关税局 (AHTAPol) 发布的建议选择的，该建议明确提到了其他国家和机构。因此，除波兰外，分析中还包括英格兰、苏格兰、威尔士、爱尔兰、法国、荷兰、德国、挪威、瑞典、加拿大、澳大利亚和新西兰。通过系统检索 PubMed (Medline)、Embase 和 The Cochrane 图书馆以及主管当局网站和灰色文献来源收集相关信息和数据。结果与讨论：在大多数国家，报销申请的提交是由制药公司发起的，只有少数国家允许在产品批准上市之前提交报销申请。所分析的所有机构都是独立的，并且有些机构具有报销决策机构的监管职能。在 HTA 方面区分不同机构的一个关键标准是成本效益阈值。大多数国家都有具体机制来改善昂贵的特种药物的获取，包括癌症药物和用于罕见疾病的药物。报销系统在评估同一阶段时往往缺乏一致性，从而导致决策过程的异构性。对不同国家针对同一药品发布的建议进行分析将有助于更好地理解报销制度、HTA 评估、利益相关者参与和创新药物报销决策之间的关系。版权所有 © 2023 Mela, Rdzanek, Jaroszyński, Furtak- Niczyporuk、Jabłoński 和 Niewada。

Introduction: Our objective was to analyze and compare systematically and structurally reimbursement systems in Poland and other countries. Methods: The systems were selected based on recommendations issued by the Polish Agency for Health Technology Assessment and Tariffication (AHTAPol), which explicitly referred to other countries and agencies). Consequently, apart from Poland, the countries included in the analysis were England, Scotland, Wales, Ireland, France, Netherlands, Germany, Norway, Sweden, Canada, Australia and New Zealand. Relevant information and data were collected through a systematic search of PubMed (Medline), Embase and The Cochrane Library as well as competent authority websites and grey literature sources. Results and discussion: In most of the countries, the submission of a reimbursement application is initiated by a pharmaceutical company, and only a few countries allow it before a product is approved for marketing. All of the agencies analyzed are independent and some have regulatory function of reimbursement decision making body. A key criterion differentiating the various agencies in terms of HTA is the cost-effectiveness threshold. Most of the countries have specific mechanisms to improve access to expensive specialty drugs, including cancer drugs and those used for rare diseases. Reimbursement systems often lack consistency in appreciating the same stages, leading to heterogeneous decision-making processes. The analysis of recommendations issued in different countries for the same medicinal product will allow a better understanding of the relations between the reimbursement system, HTA assessment, stakeholders involvement and decision on reimbursement of innovative drugs.Copyright © 2023 Mela, Rdzanek, Jaroszyński, Furtak-Niczyporuk, Jabłoński and Niewada.